glp 1 generic drugs Comparing Ozempic, Wegovy and Other GLP-1 America's Poison Centers - GLP-1
Description
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
The studys limitations include its reliance on a US sample and a retrospective design, which may introduce bias and limit generalizability
LNP-mediated in vivo DNA delivery in the mouse liver Efficient delivery of donor DNA, along with Cas9 and gRNA, is crucial for successful in vivo HITI
M.BushongE
You do not need diabetes to benefit from these peptides
Article information 1
